![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Direxion Daily Energy Bull 2X Shares ETF
ERX
Direxion Daily Semiconductor Bull 3x Shares ETF
SOXL
United States Natural Gas
UNG
4
ProShares Ultra Materials
UYM
5
VanEck Oil Services ETF
OIH
US Stock MarketDetailed Quotes
Cardiff Oncology (CRDF)
- 1.600
- +0.120+8.11%
Close Feb 6 16:00 ET
- 1.580
- -0.020-1.25%
Post 20:01 ET
107.78MMarket Cap-2.03P/E (TTM)
1.620High1.500Low927.42KVolume1.510Open1.480Prev Close1.46MTurnover1.41%Turnover RatioLossP/E (Static)67.36MShares4.99052wk High2.21P/B105.17MFloat Cap1.48052wk Low--Dividend TTM65.73MShs Float81.480Historical High--Div Yield TTM8.11%Range %0.450Historical Low1.576Avg Price1Lot Size
CRDF Stock Chart
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
CRDF Orderflow
Unit: --
CRDF Orderflow Trend
IntradayDayWeekMonth
No Data
Cardiff Oncology (CRDF) News
Cardiff Oncology Analyst Ratings
Noble Financial Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Maintains Target Price $12
Analysts Are Bullish on Top Healthcare Stocks: Cardiff Oncology (CRDF), Codexis (CDXS)
H.C. Wainwright Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Maintains Target Price $10
Cardiff Oncology Stock Plunges After Sudden Leadership Change, Narrowed Trial Focus
Cardiff Oncology Selloff Brings Attractive Entry Point, Says H.C. Wainwright
Cardiff Oncology (CRDF) Stock Forum
$Cardiff Oncology (CRDF.US)$ is the coin flipping? close watch
$Cardiff Oncology (CRDF.US)$ Reuters
1m
Cardiff Oncology Announces Positive Update From Its Randomized Phase 2 Trial of Onvansertib in First-** Ras-Mutated Mcrc!
Onvansertib Continues to Be Safe and Well-Tolerated!
Expects Final Data and Plans in H1 2026
1m
Cardiff Oncology Announces Positive Update From Its Randomized Phase 2 Trial of Onvansertib in First-** Ras-Mutated Mcrc!
Onvansertib Continues to Be Safe and Well-Tolerated!
Expects Final Data and Plans in H1 2026
2
$Cardiff Oncology (CRDF.US)$
Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025
Monday, 8th December at 4:05 pm
SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that clinical data from an investigator-sponsored trial with onvansertib in ...
Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025
Monday, 8th December at 4:05 pm
SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that clinical data from an investigator-sponsored trial with onvansertib in ...
$Cardiff Oncology (CRDF.US)$
when are you back to 4?
when are you back to 4?
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)